Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Position Raised by Swiss National Bank

Swiss National Bank increased its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 13.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 41,873 shares of the company’s stock after purchasing an additional 5,100 shares during the period. Swiss National Bank’s holdings in Enliven Therapeutics were worth $942,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after buying an additional 1,275 shares during the period. Verition Fund Management LLC purchased a new stake in Enliven Therapeutics in the 3rd quarter worth about $271,000. SG Americas Securities LLC boosted its position in Enliven Therapeutics by 66.1% during the 4th quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock worth $374,000 after acquiring an additional 6,616 shares during the period. The Manufacturers Life Insurance Company grew its stake in Enliven Therapeutics by 25.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after acquiring an additional 3,518 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in Enliven Therapeutics during the 3rd quarter valued at about $559,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ELVN. HC Wainwright raised their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 21st. BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Enliven Therapeutics has an average rating of “Buy” and a consensus price target of $38.75.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $21.07 on Friday. The business has a 50 day simple moving average of $21.28 and a 200 day simple moving average of $23.74. Enliven Therapeutics, Inc. has a 52 week low of $15.96 and a 52 week high of $30.03. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 1,000 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00. Following the completion of the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at approximately $325,520. This represents a 7.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total value of $257,625.00. Following the completion of the sale, the insider now directly owns 1,002,688 shares in the company, valued at approximately $20,665,399.68. This represents a 1.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,434 shares of company stock worth $1,558,673. Corporate insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.